Saturday, December 7, 2019
Redactor's Choice
You are here: Home / Tag: pfizer (page 4)

Tag: pfizer

New survey highlights the impact of menopausal symptoms on women in the workplace

pain

Some menopausal symptoms can be more problematic than others in the workplace. Hot flashes (31 percent), changes in memory and concentration (19 percent), and fatigue due to sleep disturbances (18 percent) rank most troublesome. The good news is that a few simple adjustments to everyday routines and understanding co-workers may help. "Menopausal symptoms impacted the women in our survey — for example, approximately one in 10 women strongly or somewhat agrees that she had passed up a more demanding position due to her menopausal symptoms. And... Read More »

American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates

science2

The goal of this public health initiative is to meet the National Vaccine Advisory Committee’s standards for adult immunization. The standards call on all health care providers to assess vaccine status at each visit, strongly recommend vaccinations to patients, administer or refer for immunization, and document vaccination. Current vaccination rates for recommended vaccines in the U.S. fall far short of those goals, with all rates well below 70 percent and fraught with racial and ethnic disparities1. “As a national organization of internists... Read More »

Pfizer prices $4.5 billion debt offering

money

Pfizer intends to use the net offering proceeds for general corporate purposes, including (i) pre-funding the repayment at maturity of the €900 million outstanding of its 4.75% notes due December 2014 and (ii) pre-funding a portion of its outstanding 5.35% notes due March 2015. Pfizer may use funds that are not immediately needed for these purposes to temporarily invest in short-term marketable securities or repay a portion of its outstanding commercial paper. The closing of the offering is expected to occur on May 15, 2014, subject to satis... Read More »

Pfizer announces positive phase 2 study results for investigational Meningococcal B Vaccine

science10

“Disease caused by meningococcus serogroup B is serious and unpredictable. The disease is difficult to recognize early and progresses rapidly, making preventive vaccination especially important,” said Dr. Emilio Emini, senior vice president of Vaccine Research and Development for Pfizer Inc. “We are encouraged by the safety and tolerability data for our investigational vaccine candidate, bivalent rLP2086, and its potential to help prevent this devastating disease. We look forward to continuing the development of this critically-needed vaccine a... Read More »

Pfizer Announces Positive Top-Line Results From Two Phase 3 Trials Of Tofacitinib In Adults With Moderate-to-Severe Chronic Plaque Psoriasis

medical

No new safety signals for tofacitinib were observed in the OPT Pivotal #1 or OPT Pivotal #2 studies. Detailed analyses of these studies, including additional efficacy and safety data, will be submitted for presentation at a future scientific meeting. “Psoriasis is a long-term disease with no cure that can have a significant impact on patients. Although it is one of the most common chronic inflammatory diseases, many psoriasis patients remain untreated, undertreated or dissatisfied with their treatment, according to recently published surveys... Read More »

Pfizer Invites Public To Listen To Webcast Of April 24 Annual Meeting Of Shareholders

video

fizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 24. To access the webcast, visit our website at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. ... Read More »

Advil® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick Off a Nationwide “Relief” Tour

corporate

“Growing up, my family was always volunteering, so I learned early on the importance of communities coming together to help one another,” said Josh Duhamel. “It wasn't until I started organizing events for disasters in Haiti and Japan, and then again in my hometown of Minot, N.D., that I truly understood and appreciated the tireless and tough work of volunteers. To me, the Advil® Relief in Action campaign means knowing that others are counting on you, and doing whatever it takes to help. That includes not letting pain get in the way of giving b... Read More »

Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole significantly prolonged progression-free survival in patients with advanced breast cancer

pill

"These data demonstrate the potential of palbociclib to be a major advance in the treatment of women with this type of advanced breast cancer," said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "We are proud to be at the forefront of research and development with respect to this promising new class of investigational anticancer agents and have initiated a broad clinical development program for palbociclib that includes breast and non-breast cancers.” Fin... Read More »

Bococizumab significantly reduced LDL cholesterol In statin-treated adults with high cholesterol in A Phase 2b Study

pill

Elevated LDL-C is recognized as a major risk factor for cardiovascular disease,2 the number one cause of death worldwide despite the widespread availability of statin therapy. “I am hopeful that bococizumab, as a member of the PCSK9 class, will play an important role in understanding and addressing the unmet need for patients at high risk for cardiovascular events. The Phase 3 CV outcome studies for this class of medicine will be the most critical in defining future clinical practice,” said Christie M Ballantyne, Chief of the Section of Card... Read More »

Pfizer Announces Detailed Results of OPT Compare Phase 3 Study

pulse

Pfizer Inc.  announced today detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Top-line results from OPT Compare were previously announced in October 2013. This is the first of five studies from the Phase 3 Oral treatment Psoriasis Trial (OPT) Program, one of the largest global clinical trial programs in moderat... Read More »

Scroll To Top